International HTA Agencies Collaborate On How To Determine Value-Based Prices
Health technology assessment agencies in the US, the UK and Canada are working together to develop new ways of determining value-based prices for potentially curative treatments like gene therapies.
You may also be interested in...
Canada has launched a new initiative under which drug sponsors will be able to request parallel scientific advice for regulatory and health technology assessment purposes.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.